Supernus Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Supernus Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- SUPN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001356576
Board of directors
-
Bethany Sensenig · DirectorSince 2023
-
Carrolee Barlow · DirectorSince 2023
-
Charles W. Newhall III · DirectorSince 2023
-
Frederick M. Hudson · DirectorSince 2023
-
Georges Gemayel · DirectorSince 2023
-
Jack A. Khattar · Director · President, CEOSince 2023
-
John M. Siebert · DirectorSince 2023
Chief executives
Jack A. Khattar
· President, CEO
Dates unknown
Board connections
2 of this board's directors also sit on 2 other boards.
- via Jack A. Khattar
- via Georges Gemayel
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 27, 2024 | Rubin Jonathan Officer (SVP, Chief Medical Officer) | Option exercise | +750 | — | — |
| Dec 27, 2024 | Jack A. Khattar Director, Officer (President, CEO) | Option exercise | +38,640 | — | — |
| Dec 27, 2024 | Rubin Jonathan Officer (SVP, Chief Medical Officer) | Shares withheld for tax | −281 | $35.59 | $10,001 |
| Dec 27, 2024 | Jack A. Khattar Director, Officer (President, CEO) | Shares withheld for tax | −18,567 | $35.59 | $660,800 |
| Dec 27, 2024 | Rubin Jonathan Officer (SVP, Chief Medical Officer) | Option exercise | +1,875 | — | — |
| Dec 27, 2024 | Jack A. Khattar Director, Officer (President, CEO) | Option exercise | +14,000 | — | — |
| Dec 27, 2024 | Rubin Jonathan Officer (SVP, Chief Medical Officer) | Shares withheld for tax | −821 | $35.59 | $29,219 |
| Dec 27, 2024 | Jack A. Khattar Director, Officer (President, CEO) | Shares withheld for tax | −6,666 | $35.59 | $237,243 |
| Dec 3, 2024 | Bhatt Padmanabh P. Officer (Sr. VP of IP, CSO) | Option exercise | +8,750 | $23.99 | $209,913 |
| Dec 3, 2024 | Bhatt Padmanabh P. Officer (Sr. VP of IP, CSO) | Open-market sale | −8,750 | $36.68 | $320,950 |
| Dec 3, 2024 | Bhatt Padmanabh P. Officer (Sr. VP of IP, CSO) | Option exercise | +12,745 | $25.30 | $322,449 |
| Dec 3, 2024 | Bhatt Padmanabh P. Officer (Sr. VP of IP, CSO) | Open-market sale | −12,745 | $36.68 | $467,487 |
| Nov 11, 2024 | Charles W. Newhall III Director | Option exercise | +20,000 | $9.13 | $182,600 |
| Nov 11, 2024 | Charles W. Newhall III Director | Open-market sale | −10,700 | $36.24 | $387,768 |
| Nov 8, 2024 | Frederick M. Hudson Director | Open-market sale | −8,722 | $36.28 | $316,434 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.